Sureerat Suwatcharangkoon, MD; Emma Meyers, BA; Cristina Falo, PhD; et al.
free access
has audio
JAMA Neurol. 2016;73(1):28-35. doi:10.1001/jamaneurol.2015.3188
This retrospective analysis reports that loss of consciousness at onset of subarachnoid hemorrhage is associated with death or severe disability at 12 months.
-
Podcast:
Loss of Consciousness at Onset of Subarachnoid Hemorrhage (JAMA Neurology)
-
Editorial
Subarachnoid Hemorrhage and Loss of Consciousness
R. Loch Macdonald, MD, PhD
JAMA Neurol
Hyung-Min Kwon, MD, PhD; Michael J. Lynn, MS; Tanya N. Turan, MD; et al.
free access
JAMA Neurol. 2016;73(1):36-42. doi:10.1001/jamaneurol.2015.3145
This post hoc analysis of a clinical trial evaluated the risk of ischemic stroke in patients with large artery atherosclerosis and coexistent small vessel disease.
Thabele M. Leslie-Mazwi, MD; Joshua A. Hirsch, MD; Guido J. Falcone, MD, MPH; et al.
free access
JAMA Neurol. 2016;73(1):43-49. doi:10.1001/jamaneurol.2015.3000
This cohort study of patients with anterior circulation ischemic stroke compared outcomes after thrombectomy of patients classified as likely vs unlikely to benefit from the procedure based on clinical criteria and MRI findings.
Ying Xian, MD, PhD; Jerome J. Federspiel, MD, PhD; Maria Grau-Sepulveda, MD, MPH; et al.
free access
JAMA Neurol. 2016;73(1):50-59. doi:10.1001/jamaneurol.2015.3106
This observational study using data from the Get With the Guidelines鈥揝troke registry investigates the risks and benefits associated with long-term antiplatelet therapy among adult patients with ischemic stroke who receive intravenous tissue plasminogen activator.
Henrik Zetterberg, MD, PhD; Tobias Skillbäck, MD; Niklas Mattsson, MD, PhD; et al.
free access
JAMA Neurol. 2016;73(1):60-67. doi:10.1001/jamaneurol.2015.3037
This cross-sectional study compares cerebrospinal fluid neurofilament light concentrations in patients with Alzheimer disease, mild cognitive impairment, and normal cognition, and associations with cognitive deterioration and structural brain changes.
Janice L. Farlow, PhD; Laurie A. Robak, MD, PhD; Kurt Hetrick, MS; et al.
free access
JAMA Neurol. 2016;73(1):68-75. doi:10.1001/jamaneurol.2015.3266
Using a 2-stage exome sequencing design, this study identifies genetic variants contributing to disease risk in familial Parkinson disease.
Laura Eisenmenger, MD; Marie-Claire Porter, MD; Christopher J. Carswell, PhD; et al.
free access
JAMA Neurol. 2016;73(1):76-84. doi:10.1001/jamaneurol.2015.3159
This study assesses gray matter involvement on diffusion-weighted imaging in patients with sporadic Creutzfeldt-Jakob disease and investigates the potential of these images as a biomarker of disease progression.
Ronald C. Petersen, PhD, MD; Heather J. Wiste, BA; Stephen D. Weigand, MS; et al.
free access
JAMA Neurol. 2016;73(1):85-92. doi:10.1001/jamaneurol.2015.3098
This population-based, longitudinal study of cognitively normal individuals reports that elevated amyloid levels are associated with worse cognition and imaging biomarkers and greater clinical decline and neurodegeneration.
Rosebud O. Roberts, MB, ChB; Teresa J. H. Christianson, BS; Walter K. Kremers, PhD; et al.
free access
JAMA Neurol. 2016;73(1):93-101. doi:10.1001/jamaneurol.2015.2952
This study measured olfactory impairment and its association with mild cognitive impairment or dementia due to Alzheimer disease.
The Huntington Study Group PHAROS Investigators
free access
JAMA Neurol. 2016;73(1):102-110. doi:10.1001/jamaneurol.2015.2736
This cohort study evaluates the use of measures associated with cytosine-adenine-guanine (CAG) expansion that can be determined to identify individuals with CAG expansion before the diagnosis of Huntington disease.